Fri, Dec 19, 2014, 8:25 AM EST - U.S. Markets open in 1 hr 5 mins

Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • joeflow77 joeflow77 Jan 15, 2011 11:34 PM Flag

    EXEL is one IND and one fasttracker away form 3 Billion.

    Clem, DNDN does not have a "drug". Provenge is a method wherein a patients peripheral blood lymphocytes are removed and stimulated with a specific antigen commonly expressed on prostate cancer cells. Protocol includes the addition of growth factors (cytokines such as IL-2) to stimulate the growth of cytotoxic T cells that should specifically attack prostate cancer cells. These cells are then re-infused back into the patient. Results are modest at best and barely reach statistical significance. The concept is based on work done by Steve Rosenberg in the late 1980-1990s when Rosenberg was injecting metastatic melanoma patients with IL-2 in an attempt to stimulate a T cell response directed at cancer cells. Rosenberg's attempts were a failure and many terminal patients suffered needlessly while Rosenberg tried to make a name for himself. I was at Columbia University at the time and when Rosenberg came to give a talk on his "research" the Chairman of Hematology and Oncology at Columbia declared him to be a madman that should not be allowed to experiment on human beings.
    There is no comparison between DNDN and EXEL with XL184. XL184 is a drug, administered as a pill, and has shown dramatic efficacy in PhaseII trials. Insurance companies will refuse to pay for DNDN's experimental protocol just as they did with bone marrow transplants because the efficay and duration of response is not worth the high price tag. DNDN will be out of business in a few years.

    my not so humble opinion, Joe

 
EXEL
1.35-0.010(-0.74%)Dec 18 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Orexigen Therapeutics, Inc.
NASDAQThu, Dec 18, 2014 4:00 PM EST